Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24818595 | 1.00 | ANPEP (0.37) | ANPEPADH1BADH1CADH1A | |
| SCHEMBL20301671 | 1.00 | ANPEP (0.37) | ANPEPADH1BADH1CADH1A | |
| SCHEMBL7077043 | 0.91 | — | — | |
| SCHEMBL64203 | 0.78 | — | — | |
| SCHEMBL3557239 | 0.78 | — | — | |
| SCHEMBL6522093 | 0.78 | ANPEP (0.37) | ANPEPADH1BADH1CADH1A | |
| SCHEMBL19826376 | 0.77 | — | — | |
| SCHEMBL399646 | 0.75 | — | — | |
| Methane SCHEMBL9112529 | 0.75 | ADH1B (0.47) | ANPEPADH1BADH1CADH1A | |
| Ammonia Solution, Strong SCHEMBL12490708 | 0.75 | ADH1B (0.47) | ANPEPADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-10899754-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-26 | — | — | US | disclosed |
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| EP-3558978-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018116107-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | ANPEP 1831/4885ADH1B 1558/4885ADH1C 1213/4885 |
| US-10899754-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | ANPEP 1831/4885ADH1B 1558/4885ADH1C 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.